All In Biotech

Drug Trial Radar · NCT02107872

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Last checked: Nov 20, 2026Latest source record: Sep 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Apr 2014

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, pharmacokinetic (PK), immunogenicity, and pharmacodynamic (PD) effects of REGN1500 in patients with a metabolic disorder.

Conditions

  • Metabolic Disorders

Interventions

  • REGN1500Drug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: visit 1 to day 183 (EOS)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Evansville, Indiana

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.